aIncludes paronychia, nail infection, nail bed infection. bIncludes stomatitis, aphthous stomatitis, mucosal inflammation, mouth ulceration, oral mucosa erosion, mucosal erosion, mucosal ulceration. cIncludes group of rash preferred terms. dIncludes acne, acne pustular, dermatitis acneiform. eIncludes pruritus, pruritus generalised. fIncludes dry skin, skin chapped. gIncludes nail disorder, onycholysis, nail toxicity, onychoclasis, ingrowing nail, nail pitting, onychomadesis, nail discoloration, nail dystrophy, nail ridging, and onychogryphosis. hBased on post-marketing experience.
Adapted from GIOTRIF® (afatinib), Summary of Product Characteristics, 2018.1
ADR=adverse drug reaction, AE=adverse event, NSCLC=non-small-cell lung cancer
You're now leaving our website...
Click here for international product information intended for Healthcare Professionals about afatinib for non-small-cell lung cancer treatment.
Click here for general international information about afatinib for non-small-cell lung cancer treatment.